News Headlines

  1. Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement To Fund Initiation Of The First Phase 3 Celiac Disease Clinical Trial

    Innovate Biopharmaceuticals, Inc. (“Innovate” or the “Company”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that on March 17, 2019, it entered into an agreement (the “Agreement”) with SDS Capital Partners II LLC and certain other accredited investors (together, the “Purchasers”) providing for the sale by the Company at a purchase price of $2.33 per share as further described below of up to 4,291,845 shares (the “Shares”) of its common stock (the “Common Stock”), up to 2,575,107 five-year term warrants with an exercise price as further described below at a premium to the purchase price and up to 4,291,845 12-month term warrants at an exercise price of $4.00 (total of up to 6,866,952 shares of Common Stock).

  2. EMA Grants Orphan Medicinal Product Designation For Retrotope’s RT001 In The Treatment Of Infantile Neuroaxonal Dystrophy (INAD), A PLA2G6 Associated Neurodegeneration (PLAN)

    Retrotope received notification from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) that its request for orphan medicinal product designation for the treatment of INAD with RT001, a chemically-fortified polyunsaturated fatty acid drug, has been granted by the European Commission.

  3. aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring

    aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a research collaboration and option agreement with global biotherapeutics leader CSL Behring, for the development of product candidates derived from up to four tRNA synthetases from aTyr’s preclinical pipeline.

  4. ProQR Doses First Patient In Phase 1/2 STELLAR Trial Of QR-421a For Usher Syndrome Type 2

    ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are expected to be announced mid-2019.

  5. Worldwide Clinical Trials And Deep Lens Enter Strategic Alliance To Accelerate Recruitment And Development Timelines For Oncology Trials

    Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global CRO, and Deep Lens, an AIdriven digital pathology company focused on disease diagnosis confirmation and clinical trial recruitment, recently announced a new strategic alliance in oncology.

  6. Zynerba Pharmaceuticals Initiates Phase 2 Trial Of Zygel In Autism Spectrum Disorder

    Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that it has initiated the Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial.

  7. TYME Continues To Expand Pipeline Of Cancer Metabolism-Based Therapies To Potentially Benefit Patients With Difficult-To-Treat Cancers

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced the addition of a new pre-clinical development candidate, TYME-18, to the Company’s pipeline of medical innovation.

  8. Successful Treatment Of 'London Patient' Underscores Clinical Potential Of Enochian Biosciences’ Gene Modified Cellular Therapy For HIV

    Enochian Biosciences, Inc. (Nasdaq: ENOB), a biotechnology company developing potentially curative and preventative genetically modified cellular and immune-therapy platforms to transform the lives of persons living with HIV and cancer patients, welcomes the published report of “the London patient,” the second person to potentially be cured of HIV.

  9. Ambrx And Beigene Announce Global Research And Development Collaboration To Develop Next-Generation Biologics

    Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of innovative protein therapeutics and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a global research and development collaboration.

  10. Phase 2 Clinical Trial Of Bermekimab Shows Potential New Standard Of Care For Treatment Of Hidradenitis Suppurativa, Including Significant Pain Reduction Without Antibiotics

    XBiotech (NASDAQ: XBIT) today released findings for its Phase 2 clinical study for bermekimab presented at the American Academy of Dermatology’s annual meeting which concluded today.